Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder in which gastrointestinal dysfunction and gut microbiota alterations may precede motor manifestations. Diet is a major modifiable determinant of microbial composition and metabolic activity and therefore shapes the production of metabolites involved in gut–brain communication. This review examines the diet–microbiota–metabolite axis in PD, with emphasis on microbial signals beyond short-chain fatty acids. We integrate evidence on tryptophan and aromatic amino acid catabolites, bile acids, biogenic amines, bacterial lipids, trimethylamine N-oxide, polyamines, and other diet-responsive metabolites, and discuss their relationships with intestinal barrier function, neuroinflammation, mitochondrial dysfunction, α-synuclein pathology, and epigenetic regulation. Metabolomic and multi-omics approaches are considered as tools for linking nutritional exposures to microbial function and host metabolic phenotypes, while accounting for biological matrix, medication, and disease stage. Particular attention is given to interactions among diet, gut microbial metabolism, and levodopa (L-DOPA) bioavailability, alongside probiotics, prebiotics, postbiotics, and food-first interventions. Current evidence provides a research framework for future hypothesis-testing toward microbiome-informed dietary strategies and precision nutrition, but causal inference remains limited by cross-sectional designs, heterogeneous analytical protocols, and insufficient dietary characterization.
No takes yet. Share an insight, caveat, or question.
Gątarek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: